Home
Team
Blog
Experts
Careers
Projects
Code of Conduct
Press
Publications
Contact Us
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hematology
How do you counsel young patients undergoing cladribine therapy for hairy cell leukemia in terms of risk of secondary malignancy and infertility?
Related Questions
How if at all does your treatment of limited-stage double hit lymphoma (DHL) differ from treatment of advanced stage DHL?
How would you manage Stage IE DLBCL of the breast?
How would you manage a patient with history of follicular lymphoma treated with Bendamustine-Rituximab who now has a new FDG avid lesion that is biopsy proven CD30 positive CD20 negative DLBCL?
How do you approach patients with a history of lymphoma in remission who are in need of immunosuppressive (e.g. TNF blockers, 6MP) or other therapies (e.g. JAK inhibitors) for autoimmune disease that have been linked with the development of lymphoma?
Would you use R2CHOP to treat DLBCL based on the results of the E1412 study?
How would you manage a patient with Stage IVB DLBCL with refractory disease in the retroperitoneum and spleen after 6 cycles of RCHOP?
Would you offer treatment for asymptomatic CLL with WBC of ~300k or greater, high risk cytogenetics, or doubling time of 6-12 months?
Would you initiate chemoimmunotherapy (e.g. RCHOP) in a symptomatic patient with DLBCL who tested positive for COVID19?
How would you manage a stage IE DLBCL of the stomach, non-germinal center type by IHC, and Ki-67 of 70%, but negative for double/triple hit by FISH?
In a patient newly diagnosed with mantle cell lymphoma who has focal intracerebral disease and has received SRS, what is the benefit to adding a BTK-inhibitor such as ibrutininb to chemotherapy?
